Multiple Dose, Dose Response Over 24 Hours Using the Novel, Topical Carbonic Anhydrase Inhibitor MK-927
The multiple dose, dose response curve of the topical carbonic anhydrase inhibitor MK-927 administered every 12 h was investigated in 20 patients with primary open-angle glaucoma or ocular hypertension. Three concentrations of MK-927 (2%, 1%, and 0.5%) and placebo were administered in a double-blind randomized, placebo-controlled, 14 day parallel study by means of multiple 25 h diurnal intraocular pressure curves measured at one center within the framework of a larger, five center trial. Fourteen days of dosing with 2% MK-927 given every 12 h significantly decreases intraocular pressure through 12 h postdose (peak mean decrease in the worse eye of 7.4 mm Hg and mean percent decrease of 26% at 2 h postdose) compared to prestudy. A numerical dose response relationship was observed and 0.5% MK-927 given twice daily appears to be a minimal-effect dose.
KeywordsOcular Hypertension Ophthalmic Solution Active Carbonic Anhydrase Carbonic Anhydrase Inhibitor Benzalkonium Chloride
Unable to display preview. Download preview PDF.
- Baldwin JJ,Ponicello GS, Sugrue MF, Mallorga PJ, Randall WC, Schwam H, Springer JP, Smith GM, Murcko M (1988) MK-927, a water soluble, topically effective carbonic anhydrase inhibitor. Abstract #95, Medicinal Chemistry Section, Third Chemical Congress of North America, Toronto, Canada, June 5, 1988Google Scholar
- Baldwin J, Ponticello G, Anderson P, Christy M, Murcko M, Randall W, Schwam H, Sugrue M, Springer J, Gautheron P, Grove J, Mallorga P, Viader MP, McKeever B, Navia M (1989) Thienothiopyran-2-sulfonamides: Novel topically active carbonic anhydrase inhibitors for the treatment of glaucoma. Communication to the editor. J Med Chem 32:2510–2513PubMedCrossRefGoogle Scholar
- Buclin T, Lippa E, Biollaz J, Brunner-Ferber F, Schoeneich M, Faggionni R, Munafo A, Schelling J (1989) Absence of metabolic effects of the novel topically active carbonic anhydrase inhibitor MK-927 and its S-isomer during a two-week ocular administration. European J Clin Pharmacol 36 (suppl): pp 05.46Google Scholar
- Hennekes R, Pfeiffer N, Lippa E, Garus H, Grehn F, Jaeger A (1988) An active topical carbonic anhydrase inhibitor in patients. Invest Ophthalmol Vis Sci 29 (suppl): 82Google Scholar
- Maren T, Bar-Ilan A (1988) Ocular pharmacology and hypotensive activity of a topically active carbonic anhydrase (CA) inhibitor, a 4-alkylamino-thienothiopyran-2-sulfonamide, MK-927. Invest Ophthal Vis Sci 29 (suppl): 16Google Scholar
- Sugrue M, Gautheron P, Grove J, Mallorga P, Schwam H, Viader P, Baldwin J, Ponticello G (1988) MK-927: A topically effective ocular hypotensive carbonic anhydrase inhibitor in rabbits. Invest Ophthalmol Vis Sci 29 (suppl): 81Google Scholar
- Tuulonen A, Hovding G, Gustad L, Dithmer O, Monestam E, Lippa E, Krogh E, Alm A, Calissendorff B, Aasved H, Bertelsen T, Airaksinen PJ (1989) Multiple-dose dose-response curve of the topical carbonic anhydrase inhibitor MK-927. Invest Ophthalmol Vis Sci 30 (suppl): 24Google Scholar
- Wang RF, Serle J, Podos S, Sugrue M (1988) The ocular hypotensive effect of the topical carbonic anhydrase (CA) inhibitor MK-927 in glaucomatous monkeys. Invest Ophthalmol Vis Sci 29 (suppl): 16Google Scholar